Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support

被引:96
作者
Grebely, Jason [1 ]
Knight, Elizabeth [2 ]
Genoway, Krista A. [2 ]
Viljoen, Mark [3 ]
Khara, Milan [3 ]
Elliott, Doug [3 ]
Gallagher, Lesley [2 ]
Storms, Michelle [2 ]
Raffa, Jesse D. [4 ]
DeVlaming, Stanley [3 ]
Duncan, Fiona [3 ]
Conway, Brian [2 ,3 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia
[2] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
[3] Vancouver Coastal Hlth, Pender Community Hlth Ctr, Vancouver, BC, Canada
[4] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada
基金
加拿大健康研究院;
关键词
assessment; hepatitis C virus; illicit drug users; injection drug users; treatment; DIRECTLY OBSERVED THERAPY; INTERFERON-ALPHA; METHADONE-MAINTENANCE; ANTIVIRAL TREATMENT; PLUS RIBAVIRIN; HCV INFECTION; HIV; BARRIERS; REINFECTION; AUSTRALIA;
D O I
10.1097/MEG.0b013e32832a8c4c
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives We evaluated assessment and treatment for hepatitis C virus (HCV) among illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary community health centre. Methods From March 2005 to 2008, HCV-infected individuals were referred to a weekly peer-support group and assessed for HCV infection. A retrospective chart review of outcomes 3 years after the initiation of the group was conducted (including HCV assessment and treatment). Results Two hundred and four HCV antibody-positive illicit drug users accepted referral to a weekly HCV peer-support group. Assessment for HCV occurred in 53% of patients (n = 109), with 13% (n = 14) having initiated or completed treatment for HCV infection before attending the support group, evaluation ongoing in 10% (n = 11) and treatment deferred/not indicated in 25% (n = 27). The major reasons for HCV treatment deferral included early disease (30%), drug dependence (37%), other medical (11%) or psychiatric comorbidities (4%). Sixty-eight percent of those deferred for reasons other than early liver disease showed multiple reasons for treatment deferral. The first 4 weeks of support group attendance predicted successful HCV assessment (odds ratio: 6.03, 95% confidence interval: 3.27-11.12, P < 0.001). Overall, 28% (n = 57) received treatment. Among individuals having completed pegylated-interferon and ribavirin therapy with appropriate follow-up (n = 19), the rate of sustained virologic response was 63% (12/19), despite illicit drug use in 53%. Conclusion A high proportion of illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary health centre were assessed and treated for HCV infection. Peer support coupled with multidisciplinary care is an effective strategy for engaging illicit drug users in HCV care. Eur J Gastroenterol Hepatol 22: 270-277 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 40 条
[1]   Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Edlin, BR .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (10) :1540-1543
[2]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[3]   Follow-up studies of treatment for hepatitis C virus infection among injection drug users [J].
Dalgard, O .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S336-S338
[4]  
Diaz T, 2001, AM J PUBLIC HEALTH, V91, P23, DOI 10.2105/AJPH.91.1.23
[5]   Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia [J].
Doab, A ;
Treloar, C ;
Dore, GJ .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S313-S320
[6]   Prevention and treatment of hepatitis C in injection drug users [J].
Edlin, BR .
HEPATOLOGY, 2002, 36 (05) :S210-S219
[7]   Surprisingly small effect of antiviral treatment in patients with hepatitis C [J].
Falck-Ytter, Y ;
Kale, H ;
Mullen, KD ;
Sarbah, SA ;
Sorescu, L ;
McCullough, AJ .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (04) :288-292
[8]   Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada [J].
Fischer, B ;
Vasdev, S ;
Haydon, E ;
Baliunas, D ;
Rehm, J .
PRESSE MEDICALE, 2005, 34 (17) :1209-1212
[9]   Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection [J].
Fishbein, DA ;
Lo, YT ;
Reinus, JF ;
Gourevitch, MN ;
Klein, RS .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (03) :1367-1375
[10]   Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment [J].
Fleming, CA ;
Craven, DE ;
Thornton, D ;
Tumilty, S ;
Nunes, D .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :97-100